Research map: Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests

Back to the article

Papers in this map

  1. A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research · Terry K. K. Koo · 2016 · 29493 citations · Cited by this paper
  2. Quantitative Bias Analysis of Unmeasured Confounding Refines Interpretation of Longitudinal Associations Between Cardiometabolic Risk Factors and Liver Stiffness in MASLD · 2026 · Related
  3. Design and validation of a histological scoring system for nonalcoholic fatty liver disease† · David Erwin Kleiner · 2005 · 10909 citations · Cited by this paper
  4. Updates in clinical science: Alcohol-related hepatitis · 2026 · Related
  5. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡ · Richard K. Sterling · 2006 · 5001 citations · Cited by this paper
  6. Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction · 2026 · Related
  7. A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C · Chun Tao Wai · 2003 · 4424 citations · Cited by this paper
  8. OSM-STAT3 signaling facilitates Long-term expansion of Pediatric Hepatic Organoids · 2026 · Related
  9. A multisociety Delphi consensus statement on new fatty liver disease nomenclature · Mary Eugenia Rinella · 2023 · 3032 citations · Cited by this paper
  10. JHEP at a glance (August 2026) · 2026 · Related
  11. Sampling Variability of Liver Fibrosis in Chronic Hepatitis C · Pierre Bédossa · 2003 · 2237 citations · Cited by this paper
  12. Before repurposing Fusobacterium nucleatum in alcohol-associated liver disease: it is a rare, non-resident organism in the human alcoholic gut · 2026 · Related
  13. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) · Frank Tacke · 2024 · 2049 citations · Cited by this paper
  14. Declining but persistent hepatocellular cancer risk beyond 10 years of entecavir or tenofovir in chronic hepatitis B: Results of the PAGE-B cohort · 2026 · Related
  15. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis · Stephen A. Harrison · 2024 · 1982 citations · Cited by this paper
  16. Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis · 2026 · Related
  17. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies · Siddharth Singh · 2014 · 1768 citations · Cited by this paper
  18. Metabolic dysfunction profiles identify heterogeneous hepatocellular carcinoma risk in MASLD-associated advanced fibrosis · 2026 · Related
  19. From NASH to HCC: current concepts and future challenges · Quentin Mark Anstee · 2019 · 1432 citations · Cited by this paper
  20. Revisiting rejection after immune checkpoint inhibitor exposure prior to liver transplantation for hepatocellular carcinoma · 2026 · Related
  21. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management · Stuart McPherson · 2014 · 1071 citations · Cited by this paper
  22. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis · Arun J. Sanyal · 2025 · 985 citations · Cited by this paper
  23. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis · Stuart McPherson · 2016 · 945 citations · Cited by this paper
  24. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study · Philip Noel Newsome · 2020 · 800 citations · Cited by this paper
  25. Endpoints and clinical trial design for nonalcoholic steatohepatitis · Arun Jayant Sanyal · 2011 · 769 citations · Cited by this paper
  26. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers · Indra Neil Guha · 2007 · 746 citations · Cited by this paper
  27. Cytokeratin-18 Fragment Levels as Noninvasive Biomarkers for Nonalcoholic Steatohepatitis · Ariel E. Feldstein · 2009 · 712 citations · Cited by this paper
  28. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease · Mohammad Shadab Siddiqui · 2018 · 617 citations · Cited by this paper
  29. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis · Ferenc Emil Mózes · 2021 · 520 citations · Cited by this paper
  30. The Global Burden of Liver Disease · Zobair M. Younossi · 2023 · 498 citations · Cited by this paper
  31. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials · Stephen A. Harrison · 2020 · 495 citations · Cited by this paper
  32. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials · Beth A. Davison · 2020 · 449 citations · Cited by this paper
  33. Use of Liver Imaging and Biopsy in Clinical Practice · Elliot B. Tapper · 2017 · 444 citations · Cited by this paper
  34. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease · David Erwin Kleiner · 2019 · 375 citations · Cited by this paper
  35. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis · Emmanuel Anandraj Selvaraj · 2021 · 370 citations · Cited by this paper
  36. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis · Yasaman Vali · 2020 · 298 citations · Cited by this paper
  37. ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis · Samuel Joseph Daniels · 2018 · 268 citations · Cited by this paper
  38. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease · Huapeng Lin · 2024 · 242 citations · Cited by this paper
  39. Impact of non-invasive biomarkers on hepatology practice: Past, present and future · Quentin Mark Anstee · 2022 · 224 citations · Cited by this paper

Source: OpenAlex (CC0)